At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 42 enrolled
Drug / intervention
Sacubitril / Valsartan Oral Tablet [Entresto] +1 moredrug
Likely dose
Sacubitril / Valsartan Oral Tablet [Entresto] 26 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019
In Brief
A Phase 2 clinical trial evaluating Sacubitril / Valsartan Oral Tablet [Entresto] and Placebo for Covid19. Completed, enrolled 42 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the effect of sacubitril/valsartan versus placebo on markers of cardiac injury, structure, and function among patients who recovered from acute COVID-19 infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedMay 2021
Enrollment StartAug 2021
Primary CompletionJun 2023
TodayJul 2026
First PostedMay 12, 2021
Enrollment StartAug 6, 2021
Primary CompletionJun 13, 2023
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 5.1 years ago
Interventions
Sacubitril / Valsartan Oral Tablet [Entresto]drug
sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
Placebodrug
sacubitril/valsartan matching placebo tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.